Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Given Consensus Recommendation of “Buy” by Analysts

Shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) have been given a consensus rating of “Buy” by the six ratings firms that are presently covering the stock, Marketbeat.com reports. One investment analyst has rated the stock with a hold rating, four have issued a buy rating and one has assigned a strong buy rating to the company. The average 12-month target price among brokerages that have updated their coverage on the stock in the last year is $32.6667.

CPRX has been the subject of several research reports. Wall Street Zen raised shares of Catalyst Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Sunday, November 16th. Citigroup increased their price target on Catalyst Pharmaceuticals from $31.00 to $33.00 and gave the company a “buy” rating in a research note on Friday, November 7th. Weiss Ratings reaffirmed a “buy (b-)” rating on shares of Catalyst Pharmaceuticals in a research note on Monday, December 29th. Finally, Oppenheimer reaffirmed an “outperform” rating and set a $33.00 price objective on shares of Catalyst Pharmaceuticals in a report on Friday, November 7th.

Catalyst Pharmaceuticals Price Performance

CPRX stock opened at $23.08 on Monday. Catalyst Pharmaceuticals has a 1-year low of $19.05 and a 1-year high of $26.58. The business has a 50 day simple moving average of $23.86 and a two-hundred day simple moving average of $22.23. The company has a market capitalization of $2.82 billion, a price-to-earnings ratio of 13.66, a PEG ratio of 0.77 and a beta of 0.75.

Insider Buying and Selling

In other Catalyst Pharmaceuticals news, Director Molly Harper sold 26,746 shares of Catalyst Pharmaceuticals stock in a transaction on Friday, December 12th. The shares were sold at an average price of $23.25, for a total value of $621,844.50. Following the completion of the transaction, the director directly owned 2,360 shares of the company’s stock, valued at $54,870. This trade represents a 91.89% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. 10.40% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in CPRX. Parkside Financial Bank & Trust increased its stake in Catalyst Pharmaceuticals by 17.6% during the fourth quarter. Parkside Financial Bank & Trust now owns 3,138 shares of the biopharmaceutical company’s stock worth $73,000 after acquiring an additional 469 shares during the last quarter. Oregon Public Employees Retirement Fund lifted its stake in shares of Catalyst Pharmaceuticals by 1.8% in the 4th quarter. Oregon Public Employees Retirement Fund now owns 26,428 shares of the biopharmaceutical company’s stock valued at $617,000 after purchasing an additional 472 shares during the last quarter. Jones Financial Companies Lllp boosted its holdings in shares of Catalyst Pharmaceuticals by 14.0% in the 3rd quarter. Jones Financial Companies Lllp now owns 4,061 shares of the biopharmaceutical company’s stock worth $79,000 after purchasing an additional 498 shares during the period. Mission Wealth Management LP increased its position in shares of Catalyst Pharmaceuticals by 5.0% during the 2nd quarter. Mission Wealth Management LP now owns 10,620 shares of the biopharmaceutical company’s stock valued at $230,000 after purchasing an additional 510 shares during the last quarter. Finally, Lifestyle Asset Management Inc. raised its holdings in Catalyst Pharmaceuticals by 3.4% during the 4th quarter. Lifestyle Asset Management Inc. now owns 16,835 shares of the biopharmaceutical company’s stock valued at $393,000 after buying an additional 553 shares during the period. Hedge funds and other institutional investors own 79.22% of the company’s stock.

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapies for patients living with rare neuromuscular, neurological and metabolic diseases. The company’s mission centers on delivering safe and effective treatments that address unmet medical needs in small patient populations.

The company’s lead product is Firdapse® (amifampridine phosphate), a treatment approved by the U.S. Food and Drug Administration for adults with Lambert-Eaton Myasthenic Syndrome (LEMS).